Skip to content

Immunological Characteristics of Patients With PID and IBD

Immunological Characteristics of Patients With Primary Immunodeficiencies and Inflammatory Bowel Diseases

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03148028
Enrollment
45
Registered
2017-05-10
Start date
2017-05-15
Completion date
2020-12-31
Last updated
2017-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases, Primary Immune Deficiency Disorder

Brief summary

The investigators wish to characterize alterations in the architecture and function of immune cells in patients with a primary immunodeficiency that also develop inflammatory bowel disease. In addition, The investigators' goal is to characterize the microbiome of these patients, in order to determine whether specific microbial alterations are related to inflammation.

Detailed description

The pathogenesis of inflammatory bowel diseases (IBD), like Crohn's disease and ulcerative colitis is complex and is thought to be related to genetic, environmental and microbial alterations that lead to a hyperactive/dysregulated immune system that mediates tissue damage. In rare cases, IBD can develop in patients with primary immunodeficiencies (PID) who develop severe, atypical or recurrent infections. The bowel disease in these patients can present after they develop infectious complications but also prior to that. The goal of the current study is to characterize immune function in patients with PID and IBD in order to identify alterations in pro-inflammatory and regulatory pathways. The investigators will obtain blood samples from PID patients with IBD in order to perform deep immune profiling using various techniques such as flow cytometry, ELISA and others. Moreover, the investigators wish to characterize the microbiome of these patients. This multi-disciplinary approach will advance our understanding why specific patients with an immunodeficiency develop an IBD-like phenotype.

Interventions

None listed

Sponsors

Sheba Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* age \<18 years * diagnosis of an immunodeficiency * suspected or confirmed IBD

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Characterization of immune cells3 yearsFrequency of pro- and anti-inflammatory immune cell subsets including functional analysis

Secondary

MeasureTime frameDescription
Characterization of stool microbiome3 years16S analysis to identify changes in diversity and specific taxa

Countries

Israel

Contacts

Primary ContactDror S Shouval, MD
dror.shouval@sheba.health.gov.il+972-3-5305006

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026